Nootropics Index - Save on smarter supplements
Isolated phytochemicals & plant compounds

Galantamine

Galantamine / galantamine hydrobromide

Galantamine inhibits acetylcholinesterase, slowing acetylcholine breakdown. A short human trial found more lucid dreams when it was paired with sleep interruption and dream training; daytime memory enhancement and better sleep are not established. The studied single doses differ from prescription daily regimens. Compare labeled strength, immediate versus prolonged release, pack count and prescription status before comparing prices; cardiac and medication-interaction cautions matter.

CholinergicAcetylcholinesterase RelatedIsolated CompoundClinical ResearchLimited Human EvidenceDose Dependent EvidenceForm Dependent Evidence
Updated October 2026/8 min read/8 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Known galantamine hypersensitivity1U.S. labeling contraindicates galantamine in people with known hypersensitivity to galantamine hydrobromide or the product's excipients.
  • Severe hepatic or renal impairment1The cited U.S. label excludes use in severe hepatic impairment or when creatinine clearance is below 9 mL/min. Moderate impairment has dose restrictions. These cautions concern impaired clearance, not established routine organ toxicity in healthy adults.
01

What is it?

What galantamine is

1

Galantamine is a plant alkaloid and reversible acetylcholinesterase inhibitor. Medicines commonly contain the hydrobromide salt, with strength stated as the amount of galantamine. Its pharmacology differs from supplying choline as a nutrient.

Cognitive evidence depends on the population

4

The 2024 Cochrane review included 21 studies with 10,990 participants, mostly older adults. It found cognitive benefit in Alzheimer's dementia at six months, but no support for mild cognitive impairment. Neither finding establishes a daytime memory benefit in healthy users.

Lucid dreaming: a specific human result

5

In 121 analyzed workshop volunteers, lucid dreams were reported by 14% on placebo, 27% on the lower active dose and 42% on the higher active dose. Every condition included sleep interruption and mnemonic dream training. The result concerns self-reported lucid dreaming within that protocol; it is not evidence of improved sleep quality or general cognition.

02

Names, aliases and forms

Common NameGalantamine
Spelling VariantGalanthamine
Chemical Name(-)-Galantamine
Salt FormGalantamine hydrobromide
Brand NamesNivalin; Razadyne; Reminyl; Galamer
Cas Numbers357-70-0; 1953-04-4
Molecular FormulasC17H21NO3; C17H22BrNO3
InchikeysASUTZQLVASHGKV-JDFRZJQESA-N; QORVDGQLPPAFRS-XPSHAMGMSA-N
Iupac Name(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
03

Mechanisms of action

Slower acetylcholine breakdown

1

Galantamine reversibly inhibits acetylcholinesterase, increasing the availability of acetylcholine. This explains its cholinergic actions; a plausible mechanism does not establish a healthy-user cognitive benefit. The same pharmacology can affect heart rate and gastrointestinal function.

04

Potential effects and evidence map

Grade C reflects limited human evidence relevant to healthy users: one short crossover trial supports lucid dreaming within a combined behavioral protocol. It does not establish better sleep, daytime memory or focus. The stronger cognitive evidence concerns people with Alzheimer's dementia; the 2024 Cochrane review found no support for mild cognitive impairment. These populations and outcomes must remain separate.

Effect domainMagnitudeGrade
Memory / learning4
CumulativeConfidence: Medium

Patient trials provide cognitive evidence in Alzheimer's dementia, but a memory or learning benefit in healthy adults is not established.

Note Grade C represents indirect population-specific evidence for this healthy-user comparison. The dementia evidence itself is stronger.

0/5
C
Sleep quality5
AcuteConfidence: Medium

Lucid dreaming increased in a short trial; improved sleep quality was not established.

Note The human dreaming result is a separate endpoint from restorative sleep. This score is zero for sleep quality, not for lucid-dream incidence.

0/5
C
Focus / attention4
UnknownConfidence: Low

Available cited studies do not establish improved focus or study performance in healthy adults.

Note The main human synthesis concerns dementia, not healthy-user attention.

0/5
E
Mental energy / wakefulness5
UnknownConfidence: Low

The lucid-dreaming study does not establish a daytime energy or wakefulness benefit.

Note Some participants reported insomnia or next-day fatigue, rather than a measured energy benefit.

0/5
E
05

Typical dosages and timing

Typical
4-8 mg/dose
Not a recommendation
Lower bound
4 mg/dose
Profile value
Upper bound
8 mg/dose
Profile value
Single-dose research context54-8 mg/dose

The 2018 crossover study compared one oral dose per experimental night with placebo across three consecutive nights. Dosing followed a sleep interruption about 4.5 hours after lights out, alongside dream training. This is a description of the experiment, not an established daily nootropic dose, a cycling schedule or a recommendation. The product strengths in an offer list do not define a dosing regimen.

Patient-trial daily dose context416-24 mg/day

The main six-month dementia results in the Cochrane review concern divided daily doses in patients. These patient regimens do not establish an appropriate dose for healthy-user memory enhancement or lucid dreaming.

06

Timing & effect horizon

Effect horizonAcute
Acute
Half-life1Acute
~7 hours
Plasma half-life and dream timing are different1

The featured The time for blood levels to fall by half during the final elimination phase.Source is a pharmacokinetic value from U.S. prescribing information, not the duration of a cognitive benefit. The acute horizon refers to the short dreaming experiment described above. A validated onset or duration for daytime memory enhancement, or a routine healthy-user cycling schedule, is not established.

07

Safety, side effects and risk profile

Pregnancy, breastfeeding and children6
The UK SmPC reports no clinical pregnancy-exposure data and no studies in lactating women; animal studies found reproductive toxicity. It advises against breastfeeding during galantamine use and identifies no relevant pediatric use. These are population-specific cautions, not a quantified fetal-harm estimate.
Legal / regulatory risk1
Confidence: High

As of October 14, 2026, the cited United States product has human prescription-drug labeling; this does not settle every product or import rule.

Note Jurisdiction-specific buyer caution, separate from intrinsic healthy-adult base risk.

3/5
A
Interaction risk6
Confidence: High

CYP2D6/CYP3A4 inhibitors can increase exposure. Heart-rate-lowering drugs and other cholinesterase inhibitors can add pharmacodynamic risk; anticholinergics may have opposing effects.

Note Targeted medication context. Examples in the UK SmPC include paroxetine, ketoconazole, beta blockers and digoxin; combinations are not all equally hazardous.

4/5
A
Cardiovascular caution1
Confidence: High

U.S. labeling warns of bradycardia and heart block with or without known conduction disease. The rate during brief healthy-user single-dose use is not established.

Note Moderate base risk reflects a credible potentially serious intrinsic hazard, not a measured high event rate at the dream-trial doses.

3/5
A
GI discomfort5
Confidence: Medium

The short dreaming trial reported mild gastrointestinal upset among active-dose effects; one nausea-related withdrawal was outside the final analysis.

Note Mild active-dose effects overall: 12% of analyzed participants. Higher-dose dementia regimens have different, less favorable tolerability.

2/5
B
Headache / dizziness6
Confidence: Medium

Dizziness and headache appear in prescription clinical safety data; their frequency during brief lower-dose healthy use is uncertain.

Note Dizziness or somnolence can impair driving. Patient-context rates are not a direct estimate for healthy adults.

2/5
B
Liver / kidney caution1
Confidence: High

Reduced clearance matters in organ impairment. U.S. labeling limits dosing in moderate impairment and excludes severe hepatic impairment or A kidney-function estimate based on creatinine levels in urine and blood.Source below 9 mL/min.

Note A targeted contraindication and exposure caution, not evidence of routine liver or kidney injury in healthy adults.

3/5
A
Pregnancy / lactation caution6
Confidence: High

Human pregnancy and breastfeeding data are inadequate; animal reproductive toxicity is reported and the cited UK product advises against breastfeeding during use.

Note Known data gap and label precautions, separate from healthy-adult base risk; no quantified human fetal-harm rate is established.

3/5
E
Evidence uncertainty5
Confidence: High

A three-night protocol cannot establish long-term safety, rare-event frequency or routine daily use in healthy adults.

Note Uncertainty is reported separately and does not itself increase the base-risk score.

1/5
C
Base risk: moderate, with a real cardiac caution1

For brief oral exposure in generally healthy adults, moderate is the least severe defensible base rating: the U.S. label warns of slowed pulse and heart block even without known conduction disease. Low would understate that potentially serious intrinsic hazard. The short healthy-user trial does not quantify rare cardiac events, so its ordinary single-dose use is not assigned a high event rate. Higher-dose patient regimens and interacting medicines need separate assessment.

Short-study tolerability is not long-term safety5

Mild adverse effects were reported by 12% of analyzed participants on at least one active-dose night, versus 3% on placebo. Reports included gastrointestinal upset, insomnia and next-day fatigue. One person who withdrew because of nausea and one avoiding sleep disturbance were outside the final analysis. The brief trial cannot establish the safety of repeated daily use.

Other label cautions1

Prescription labels include serious skin reactions and caution for ulcer or bleeding risk, severe asthma or obstructive lung disease, seizures and bladder-outflow problems. Clinical trials did not show an excess of peptic ulcers or gastrointestinal bleeding versus placebo. These cautions have different evidence and frequency estimates; the label does not establish each as a common effect of brief lower-dose use.

08

Interactions and cautions

Exposure and heart-rate interactions6

The UK SmPC reports higher exposure with paroxetine, ketoconazole and erythromycin. Other cholinesterase inhibitors or cholinergic drugs can add effects; anticholinergics may oppose them. Beta blockers, digoxin and other heart-rate-lowering medicines create a separate cardiac caution. The label also flags anesthesia interactions with succinylcholine-type agents. These are medication-specific issues, not a reason to assume every supplement combination behaves the same way.

10

How it compares

Separate prolonged-release and other oral forms7

The Dutch product record explicitly identifies a prolonged-release capsule. A capsule filter alone does not establish prolonged release, and a tablet name alone is not enough to verify its release mechanism. Compare products whose own labels specify the same release type and active strength; the short dream experiment does not validate substituting a prolonged-release medicine.

11

Practical buying and quality notes

  • The catalog snapshot on October 14, 2026 has active product names for 4 mg and 8 mg tablets, while its form filter calls them capsules. One Galamer offer selects 4 mg/tab in its name but displays 8 mg in its labeled-amount field. Verify the actual merchant label before comparing strength or cost. For a 50-unit pack, verified 4 mg and 8 mg strengths would represent 200 mg and 400 mg of labeled galantamine respectively; an equal price per unit is not an equal price per labeled milligram. Compare the same release type and currency, then add purchase costs. This is pack arithmetic, not dose advice.
  • The Dutch regulator lists an 8 mg prolonged-release product containing 10.25 mg of galantamine hydrobromide, equivalent to 8 mg of galantamine. Compare the labeled active galantamine amount; the salt mass does not indicate extra potency. Product identity, release type and an authorized supply chain matter more than an unsupported purity or best-price claim.7
12

FAQ

Does galantamine improve sleep quality?

5

The cited human study measured lucid-dream reports, not established restorative-sleep benefit. Sleep interruption was part of every study condition, and some participants had insomnia or next-day fatigue. More vivid or lucid dreams should not be equated with better sleep.

13

References

  1. DailyMed. Galantamine immediate-release tablets: U.S. prescribing information. Label updated June 1, 2026; prescribing text revised July 2025.
  2. PubChem Compound Summary for CID 9651, Galantamine.
  3. PubChem Compound Summary for CID 121587, Galantamine hydrobromide.
  4. Lim AWY, Schneider L, Loy C. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2024;11:CD001747.
  5. LaBerge S, LaMarca K, Baird B. Pre-sleep treatment with galantamine stimulates lucid dreaming: a double-blind, placebo-controlled, crossover study. PLoS One. 2018;13(8):e0201246.
  6. SyriMed. Galantamine 4 mg/ml oral solution: UK Summary of Product Characteristics. Revised May 27, 2026; emc updated June 2, 2026.
  7. College ter Beoordeling van Geneesmiddelen. Galantamine Sandoz retard 8 mg prolonged-release capsules, RVG 107501. Product record and SmPC revised June 26, 2026.
  8. Sun Pharma. India business product list: Galamer 4 mg and 8 mg galantamine tablets. Archived manufacturer list, p. 3.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.